1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Mental health and behavioural conditions
  5. Drug misuse

Needle and syringe programmes

Public health guideline [PH52] Published: 26 March 2014

  • Guidance
  • Tools and resources
  • Evidence
  • History
  • Overview
  • What is this guidance about?
  • 1 Recommendations
  • 2 Who should take action?
  • 3 Context
  • 4 Considerations
  • 5 Recommendations for research
  • 6 Related NICE guidance
  • 7 Glossary
  • 8 References
  • 9 Summary of the methods used to develop this guidance
  • 10 The evidence
  • 11 Gaps in the evidence
  • 12 Membership of the Public Health Advisory Committee (PHAC) and the NICE project team
  • Finding more information and resources
  • Update information
  • About this guidance
Download guidance (PDF)

Guidance

  • Next

6 Related NICE guidance

6 Related NICE guidance

  • Drug misuse prevention: targeted interventions (2017) NICE guideline NG64

  • Hepatitis B and C testing: people at risk of infection (2012) NICE guideline PH43

  • Drug misuse in over 16s: opioid detoxification (2007) NICE guideline CG52

  • Drug misuse in over 16s: psychosocial interventions (2007) NICE guideline CG51

  • Naltrexone for the management of opioid dependence (2007) NICE technology appraisal guidance 115

  • Methadone and buprenorphine for the management of opioid dependence (2007) NICE technology appraisal guidance 114

  • Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C (2006) NICE technology appraisal guidance 106

  • Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B (2006) NICE technology appraisal guidance 96

  • Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C (2004) NICE technology appraisal guidance 75

  • National Institute for Health and Care Excellence (NICE)

  • Next